Skip to content
10-K

Annual Report

RenovoRx, Inc. RNXT

0001641172-25-001932

← back to feed
Filed
Apr 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 25, 2025 36.55M sh
Shares Diluted FY 2024 · Dec 31, 2023 10.29M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$10.26M
Cash And Equivalents FY 2024 · Dec 31, 2023 $1.17M
Current Liabilities FY 2024 · Dec 31, 2023 $1.18M
Total Liabilities FY 2024 · Dec 31, 2023 $4.47M
Current Assets FY 2024 · Dec 31, 2023 $1.47M
Total Assets FY 2024 · Dec 31, 2023 $1.47M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.99
Eps Basic FY 2024 · Dec 31, 2023 −$0.99
Sga Expense FY 2024 · Dec 31, 2023 $5.73M
Rd Expense FY 2024 · Dec 31, 2023 $5.67M
Net Income FY 2024 · Dec 31, 2023 −$10.23M
Operating Income FY 2024 · Dec 31, 2023 −$11.4M
Stockholders Equity FY 2024 · Dec 31, 2022 $6.16M